Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 28, 2014; 20(12): 3356-3363
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3356
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3356
Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer
Wei Deng, Qi-Wei Wang, Xiao-Tian Zhang, Ming Lu, Jie Li, Yan Li, Ji-Fang Gong, Jun Zhou, Zhi-Hao Lu, Lin Shen, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China
Author contributions: All authors contributed to this paper.
Supported by National Natural Science Foundation of China, No. 81172110; the National High Technology Research and Development Program, No. 2006AA 02A 402-B02 and No. 2012AA 02A 504; the Beijing Municipal Science and Technology Commission Program “Exploring the utilization of molecular markers in the individual treatment of gastric cancer based on the clinical research cohort”
Correspondence to: Xiao-Tian Zhang, Professor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. zhangxtxx@gmail.com
Telephone: +86-10-88196561 Fax: +86-10-88196561
Received: November 6, 2013
Revised: January 29, 2014
Accepted: March 4, 2014
Published online: March 28, 2014
Processing time: 115 Days and 5.9 Hours
Revised: January 29, 2014
Accepted: March 4, 2014
Published online: March 28, 2014
Processing time: 115 Days and 5.9 Hours
Core Tip
Core tip: Although the ACTS GC and CLASSIC trials demonstrated that postoperative chemotherapy improved overall survival after standard D2 gastrectomy, severe challenges in adjuvant settings remain unsettled, such as low D2 resection rates in some regions. Our retrospective study is complementary to large-scale phase III prospective trials, and demonstrated the efficacy and safety of postoperative platinum/fluoropyrimidines in stage II/III gastric cancer patients accordingto the updated 7th edition staging system after curative gastrectomy with standard or limited lymphadenectomy.